119 related articles for article (PubMed ID: 8791974)
1. Pancreatin preparations used in the treatment of cystic fibrosis--lipase content and in vitro release.
Walters MP; Littlewood JM
Aliment Pharmacol Ther; 1996 Jun; 10(3):433-40. PubMed ID: 8791974
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro studies of microsphere pancreatic supplements.
Littlewood JM; Kelleher J; Walters MP; Johnson AW
J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S22-9. PubMed ID: 2457072
[TBL] [Abstract][Full Text] [Related]
3. In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values.
Gan KH; Geus WP; Bakker W; Lamers CB; Heijerman HG
Aliment Pharmacol Ther; 1996 Oct; 10(5):771-5. PubMed ID: 8899086
[TBL] [Abstract][Full Text] [Related]
4. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency.
Löhr JM; Hummel FM; Pirilis KT; Steinkamp G; Körner A; Henniges F
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1024-31. PubMed ID: 19352190
[TBL] [Abstract][Full Text] [Related]
5. A comparison of two pancreatin microsphere preparations in cystic fibrosis.
Elliott RB; Escobar LC; Lees HR; Akroyd RM; Reilly HC
N Z Med J; 1992 Mar; 105(930):107-8. PubMed ID: 1553114
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.
Aloulou A; Puccinelli D; Sarles J; Laugier R; Leblond Y; Carrière F
Aliment Pharmacol Ther; 2008 Feb; 27(3):283-92. PubMed ID: 17973644
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients.
Gan KH; Heijerman HG; Geus WP; Bakker W; Lamers CB
Aliment Pharmacol Ther; 1994 Dec; 8(6):603-7. PubMed ID: 7696449
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four pancreatic extracts in cystic fibrosis.
Beverley DW; Kelleher J; MacDonald A; Littlewood JM; Robinson T; Walters MP
Arch Dis Child; 1987 Jun; 62(6):564-8. PubMed ID: 3304172
[TBL] [Abstract][Full Text] [Related]
9. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis.
Zentler-Munro PL; Fine DR; Batten JC; Northfield TC
Gut; 1985 Sep; 26(9):892-901. PubMed ID: 3849459
[TBL] [Abstract][Full Text] [Related]
10. Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.
Dutta SK; Hubbard VS; Appler M
Dig Dis Sci; 1988 Oct; 33(10):1237-44. PubMed ID: 3168696
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages.
Ansaldi-Balocco N; Santini B; Sarchi C
J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S40-5. PubMed ID: 3042938
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption.
Barraclough M; Taylor CJ
J Pediatr Gastroenterol Nutr; 1996 Jul; 23(1):45-50. PubMed ID: 8811523
[TBL] [Abstract][Full Text] [Related]
13. Characterization of all the lipolytic activities in pancreatin and comparison with porcine and human pancreatic juices.
Salhi A; Amara S; Mansuelle P; Puppo R; Lebrun R; Gontero B; Aloulou A; Carrière F
Biochimie; 2020 Feb; 169():106-120. PubMed ID: 31288050
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.
Kuhn RJ; Eyting S; Henniges F; Potthoff A
J Pediatr Pharmacol Ther; 2007 Apr; 12(2):115-28. PubMed ID: 23055848
[TBL] [Abstract][Full Text] [Related]
15. Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres.
Meyer JH; Lake R
Pancreas; 1997 Oct; 15(3):226-35. PubMed ID: 9336785
[TBL] [Abstract][Full Text] [Related]
16. Effects of product formulation on in vitro activity of pancreatic enzymes.
Dressman JB; Shtohryn LV; Diokno D
Am J Hosp Pharm; 1985 Nov; 42(11):2502-6. PubMed ID: 4073069
[TBL] [Abstract][Full Text] [Related]
17. Fibrosing colonopathy in cystic fibrosis: results of a case-control study.
Smyth RL; Ashby D; O'Hea U; Burrows E; Lewis P; van Velzen D; Dodge JA
Lancet; 1995 Nov; 346(8985):1247-51. PubMed ID: 7475715
[TBL] [Abstract][Full Text] [Related]
18. Two enteric coated microspheres in cystic fibrosis.
Williams J; MacDonald A; Weller PH; Fields J; Pandov H
Arch Dis Child; 1990 Jun; 65(6):594-7. PubMed ID: 2198848
[TBL] [Abstract][Full Text] [Related]
19. Does the commonly used pH-stat method with back titration really quantify the enzymatic digestibility of lipid drug delivery systems? A case study on solid lipid nanoparticles (SLN).
Heider M; Hause G; Mäder K
Eur J Pharm Biopharm; 2016 Dec; 109():194-205. PubMed ID: 27789354
[TBL] [Abstract][Full Text] [Related]
20. Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS.
Maev IV; Kucheryavyy YA; Gubergrits NB; Bonnacker I; Shelest EA; Janssen-van Solingen GP; Domínguez-Muñoz JE
Drugs R D; 2020 Dec; 20(4):369-376. PubMed ID: 33211277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
